Aktienanalyse zu Krystal Biotech Inc (KRYS)KRYSKrystal Biotech Inc

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Krystal Biotech Inc is a good buy right now due to its strong financial performance, evidenced by a gross margin of 94.60% in Q2 2026 and a year-to-date price change of +42.34%. The current price of $351.46 is well below the average analyst price target of $386, suggesting significant upside potential. However, the main risk is the forward P/E ratio of 43.29, which indicates that the stock is trading at a high valuation relative to its earnings.

1 analysts cover KRYS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 229.25.